Stock Analysis
Genmab A/S (GMAB) Stock Analysis
Genmab A/S (GMAB) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Genmab A/S (GMAB) currently has an AIQ Score of 77/100, indicating a bullish setup. Momentum is the strongest factor at 94/100. Risk is the weakest current factor at 58/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
GMAB at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $51.37 |
| AIQ Score | 77/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Buy |
| Market Cap | $31.48B |
| P/E Ratio (TTM) | 42.8 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.56 |
| Revenue (Q3 FY2026) | $1.19B |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.93 |
| Volume | 3.73M |
| 52-week range | $23.62-$59.97 |
| RSI 14 | 59.07 |
| 50-Day SMA | $41.15 |
| 200-Day SMA | $31.54 |
| Analyst Price Target | $55.50 |
| Next Earnings | Feb 16, 2027 |
GMABGenmab A/S
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum94
- Value71
- Quality72
- Risk resilience58
- Sentiment—
GMAB Stock Analysis Summary
Genmab A/S (GMAB) currently has an AIQ Score of 77/100, indicating a bullish setup. Momentum is the strongest factor at 94/100. Risk resilience is the weakest current factor at 58/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, GMAB has AIQ Score of 77/100 with Momentum base of 94/100 and fading Risk resilience at 58/100. Wait for component alignment before adding exposure.
Momentum (94/100) leads while Risk resilience (58/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.72% stock move · GMAB classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is GMAB Bullish or Bearish Right Now?
GMAB currently has a bullish overall setup. Momentum is the strongest factor at 94/100, while Risk Resilience is weakest at 58/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 72/100.
- - Momentum is constructive at 94/100.
- - Price is +24.83% above its 50-day SMA.
- - Analyst target implies +8.04% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (25 vs 14).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
GMAB's Technical Analysis Consensus is currently Buy, with 25 buy, 7 neutral, and 14 sell votes. GMAB's 14-day RSI is 59.07, which places the stock in a constructive momentum range. GMAB's beta is 0.93, indicating market sensitivity broadly in line with the market.
What Changed in GMAB?
The largest recent change in GMAB is Momentum moving down by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the GMAB Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
GMAB Decision Framework
Public evidence layers, setup checks, and risk context for Genmab A/S.
Genmab A/S (GMAB) Stock Analysis
Genmab A/S has an AIQ Score of 77/100 in a Bullish regime. Momentum is strongest at 94/100. Beta is 0.93, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | GMAB is in a Bullish AIQ regime with score 77/100. |
| Signal Conflict | The primary conflict is that momentum leads at 94/100 while risk lags at 58/100. |
| Factor Evidence | Momentum 94/100 · Value 71/100 · Quality 72/100 · Risk 58/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 94/100.
Momentum is 94/100 and RSI (14) is 59.1.
GMAB is in a Bullish regime at 77/100.
Risk factor is 58/100 with beta 0.93 and annual volatility 45.85%.
Current conflict: momentum leads at 94/100 while risk lags at 58/100.
GMAB Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
GMAB Fundamentals
GMAB valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
GMAB Technical Analysis
GMAB technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
GMAB Stock Catalysts
Track GMAB earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
GMAB Dividend Analysis
GMAB dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
GMAB Financial Data
GMAB revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
GMAB Risk Analysis
GMAB volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
GMAB Stock News
GMAB stock news, market tone, recent headlines, and catalyst context.
GMAB vs Biotechnology Peers
Current peer cohort: GMAB · HALO · HRMY · IDYA · IMNM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| GMAB Current stock | 77/100 | 71/100 | 94/100 | 58/100 | 1.29 | 45.85% | Current |
| HALO Halozyme Therapeutics, Inc. | 78/100 | 76/100 | 84/100 | 63/100 | 0.95 | 41.04% | GMAB vs HALO |
| HRMY Harmony Biosciences Holdings, Inc. | 73/100 | 89/100 | 66/100 | 63/100 | 0.07 | 40.59% | GMAB vs HRMY |
| IDYA IDEAYA Biosciences, Inc. | 54/100 | 39/100 | 63/100 | 61/100 | 0.14 | 44.94% | GMAB vs IDYA |
| IMNM Immunome, Inc. | 48/100 | — | 45/100 | 47/100 | 0.45 | 60.72% | GMAB vs IMNM |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for GMAB: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching GMAB
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for GMAB
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
GMAB Stock FAQ
What is GMAB stock price today?
Genmab A/S's current stock price is $51.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is GMAB bullish or bearish right now?
GMAB's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is GMAB's market cap?
GMAB's market cap is $31.48B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is GMAB's current P/E ratio?
GMAB's current P/E ratio is 42.8 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is GMAB's RSI?
GMAB's 14-day RSI is 59.07 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is GMAB above its 50-day and 200-day moving averages?
GMAB is 24.83% from its 50-day SMA and 62.87% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is GMAB's next earnings date?
GMAB's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does GMAB pay a dividend?
GMAB's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.